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ABSTRACT
In chronic lymphocytic leukemia (CLL) the occurrence and the impact of antibody 
responses toward tumor-derived antigens are largely unexplored. Our serological 
proteomic data show that antibodies toward 47 identified antigens are detectable in 
29 out of 35 patients (83%) with untreated CLL. The glycolytic enzyme alpha-enolase 
(ENO1) is the most frequently recognized antigen (i.e. 54% of CLL sera). We show 
that ENO1 is upregulated in the proliferating B-cell fraction of CLL lymph nodes. In 
CLL cells of the peripheral blood, ENO1 is exclusively expressed at the intracellular 
level, whereas it is exposed on the surface of apoptotic leukemic cells.
From the clinical standpoint, patients with progressive CLL show a higher number 
of antigen recognitions compared to patients with stable disease. Consistently, the 
anti-ENO1 antibodies are prevalent in sera from patients with progressive disease and 
their presence is predictive of a shorter time to first treatment. This clinical inefficacy 
associates with the inability of patients’ sera to trigger complement-dependent 
cytotoxicity and antibody-dependent cellular cytotoxicity against leukemic cells.
Together, these results indicate that antibody responses toward tumor-derived 
antigens are frequently detectable in sera from patients with CLL, but they are 
expression of a disrupted immune system and unable to hamper disease progression.
INTRODUCTION
Immune dysfunctions are a key feature of chronic 
lymphocytic leukemia (CLL) and frequently result in 
clinically manifest complications contributing to patients’ 
morbidity and mortality, such as opportunistic infections 
and autoimmune conditions. The impairment of the host 
immune system also correlates with disease progression 
and may reflect the attempt of the leukemic cells to evade 
immune control [1].
Perturbations of both cellular and humoral immunity 
are observed in CLL patients. The T-cell compartment 
is highly abnormal, with changes in the phenotype and 
absolute number of circulating CD4+ and CD8+ T cells 
and with the accumulation of terminally differentiated 
effector memory T cells [2]. T lymphocytes express 
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markers of exhaustion, such as upregulated PD-1, leading 
to a pronounced Th2 skewing of the T-cell responses 
[3], have reduced cytotoxic functions and an impaired 
formation of immune synapses with antigen (Ag) 
presenting cells [4]. Regulatory T cells are increased in the 
peripheral blood (PB) of patients with advanced disease 
[5], and Vγ9Vδ2 T cells display features of exhaustion 
and are negative prognosticator of a shorter time to first 
treatment (TTFT) [6].
Quantitative and qualitative changes of the humoral 
responses are also very common in patients with CLL. 
Hypogammaglobulinemia affects up to 85% of patients 
and its severity correlates with stage and duration of 
the disease and with the susceptibility to recurrent 
infections [1, 7]. On the other hand, haematopoietic-
specific auto-antibodies (Ab) are frequently observed and 
autoimmune haemolitic anemia (AIHA) and/or immune 
thrombocytopenia are rather frequent complications. 
Autoimmunity is usually due to high affinity polyclonal 
immunoglobulin (Ig) G auto-Ab that are produced by the 
non-malignant B lymphocytes and recognize red cells- or 
platelets-derived auto-Ag [4, 8].
So far, little is known on the occurrence of humoral 
immune responses toward tumor-derived Ag in CLL. In a 
previous report, Krackhardt et al. detected circulating Ab 
recognizing 14 Ag derived from primary tumor samples 
in sera from patients with CLL [9]. However, the biologic 
functions and the clinical impact of spontaneously 
occurring humoral responses directed toward tumor-
derived Ag have not been investigated.
Serological Proteome Analysis (SERPA) is a 
valuable method to detect Ag-specific Ab responses in 
human malignancies. SERPA combines electrophoretic 
separation of proteins from tumor cells, western blotting 
and mass spectrometric (MS) identification of Ag 
recognized by sera. SERPA allowed the identification 
of tumor-derived Ag able to trigger humoral immune 
responses in several solid [10–16] and hematologic tumors 
[17–20]. Dubovsky et al. have recently applied a modified 
SERPA to CLL to define new membrane-associated 
targets, and identified lymphocyte cytosolic protein 1 as 
an important factor in chemokine-induced migration of 
leukemic cells [21].
The aim of our study was to investigate the 
occurrence of humoral responses toward Ag derived from 
primary tumor cells in sera from previously untreated 
patients with CLL, also evaluating their cytotoxic function 
and the correlation with parameters of disease evolution.
RESULTS
Immunoreactivity of CLL sera toward CLL-
derived Ag and protein identification
Sera obtained from 35 patients with previously 
untreated CLL were individually screened for the 
presence of IgG-based immunoreactivity against proteins 
derived from autologous CLL cells (Figure 1A and 1B). 
To verify the CLL-specificity of the detection, 8 CLL 
proteomic maps (patients 05, 06, 10, 11, 12, 13, 16, 29) 
were individually probed with a different healthy donor’s 
(HD) serum (data not shown). Overall, the 35 CLL sera 
recognized 144 Ag (mean:4.1, min:0, max:20), whereas 
the 8 HD sera recognized only 3 Ag (mean:0.4, min:0, 
max:1) (p=0.007).
The MS analyses of the 144 Ag spots produced 
by CLL sera led to the identification of 47 proteins that 
were recurrently recognized by patients’ sera. Table 
1 summarizes the chemical features, spectrometric 
data, and frequency of recognition of 18 Ag, which 
Figure 1: Two-dimensional map of proteins from CLL cells and corresponding immunoblotting map. Total proteins 
extracted from CLL cells were separated by 2-DE, stained with Coomassie Blue (A), or transferred on nitrocellulose membranes for WB 
and probed with CLL patient’s autologous serum (B). The proteins that could be assigned to Ag spots in the WB were excised from the gel 
and treated with trypsin. The resulting fragments were analyzed by MS. The location of proteins recognized by a representative CLL serum 
(patient 29) are indicated by boxes in the proteomic map and in the corresponding WB membrane.
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Table 1: Proteins recognized by at least 3 CLL sera
MW 
(kDa)/pI
Swiss-Prot 
Accession 
number
Protein name
Sequence 
coverage 
(%)
Metched 
peptides
Mascot 
score
Recurrence of antibodies 
(%)
CLL 
patients
Healthy 
Donors p
47,481/7.10 Q6GMP2 α-Enolase (ENO1) 53 20 250 19 (54) 0 0.006
33,073/5.45 P52907
F-actin-capping protein subunit 
alpha-1 (CAZA1)
32 6 73 9 (26) 0 ns
36,201/8.57 P04406
Glyceraldehyde-3-phosphate 
dehydrogenase (G3P) 33 10 125 9 (26) 0 ns
39,550/6.20 P11177
Pyruvate dehydrogenase E1 
component subunit beta, 
mitochondrial (ODPB)
43 11 93 8 (23) 0 ns
23,031/5.10 P52566 Rho GDP-dissociation inhibitor 2 (GDIR2) 56 9 93 7 (20) 0 ns
37,462/8.97 P22626
Heterogeneous nuclear 
ribonucleoproteins A2/B1 
(HNRNPA2B1)
39 13 151 6 (17) 0 ns
53,676/5.06 P08670 Vimentin (VIME) 53 20 250 6 (17) 1 (13) ns
42,052/5.29 
42,108/5.31
Q96HG5 
P63261
Actin, cytoplasmic 1 (ACTB) - 
Actin, cytoplasmic 2 (ACTG) 39 13 145 5 (14) 0 ns
31,616/5.36 P47756 F-actin-capping protein subunit 
beta (CAPZB)
36 8 98 5 (14) 0 ns
45,753/6.86 P14902 Indoleamine 2,3-dioxygenase 1 (I23O1) 23 8 66 5 (14) 0 ns
29,843/5.57 P35232 Prohibitin (PHB) 51 10 148 5 (14) 0 ns
61,187/5,70 P10809
60 kDa heat shock protein 
(HSP60)
37 14 154 4 (11) 1 (13) ns
39,851/8.30 P04075
Fructose-bisphosphate aldolase 
A (ALDOA) 44 13 106 4 (11) 1 (13) ns
23,569/5.43 P09211
Glutathione S-transferase P 
(GSTP1) 55 7 96 4 (11) 0 ns
71,082/8.52 P11142 Heat shock cognate 71 kDa protein (HSP7C) 37 16 197 3 (9) 0 ns
49,240/6.03 Q8NFZ5
TNFAIP3-interacting protein 2 
(TNIP2)
17 8 69 3 (9) 0 ns
51,230/5.39 P61978
Heterogeneous nuclear 
ribonucleoprotein K 
(HNRNPK)
34 16 109 3 (9) 0 ns
64,720/8.46 P14866 Heterogeneous nuclear 
ribonucleoprotein L (HNRPL)
16 8 78 3 (9) 0 ns
MW, Molecular weight; pI, isoelectrical point. Sequence coverage (%) is the percentage of the protein primary sequence 
covered by peptides obtained by tripsyn digestion of the Ag spot. Matched peptides is the rate between the number of 
peptides corresponding to the primary sequence of the protein and the total number of peptides analyzed. Mascot score is a 
measure of the correspondence of peptides to the protein primary sequence.
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were recognized by at least 3 patients’ sera. Additional 
proteins recognized by less than 3 patients’ sera are 
reported in Supplementary Table S1. Only 3 proteins 
(fructose-bisphosphate aldolase A [ALDOA], 60 kDa 
heat shock protein [HSP60] and vimentin [VIME]) were 
also recognized by 1 out of 8 (13%) HD sera. Sera from 
29 out of 35 CLL patients (83%) exhibited IgG-based 
immunoreactivity toward at least 1 Ag (Table 2). Among 
these, 20 (69%) were polyreactive and recognized a 
median number of 5 Ag, with a peak of 20 Ag recognized 
by the serum of patient 22.
Sera from progressive CLL are more 
immunoreactive than sera from stable CLL
The immunoreactive status of patients was 
not associated with gender, age, Rai or Binet stage, 
lymphocytosis, monocyte and platelet counts, 
hemoglobin, β2-microglobulin or lactate dehydrogenase 
values, percentage of CD38+ or ZAP70+ cells, 
immunoglobulin heavy chain variable regions (IGHV)-
mutational status, fluorescence in situ hybridization data, 
hypogammaglobulinemia, autoimmunity, concurrent 
infections or allergies. Our cohort included 10 patients in 
active disease progression and 22 patients with a stable 
disease. For the remaining 3 patients, the disease status 
at the time of SERPA was not available. Interestingly, 
we found that patients with progressive CLL showed a 
significantly higher number of Ag recognitions compared 
to patients with stable disease (p=0.01) (Figure 2). 
Overall, median TTFT of patients was 29 months and 
median overall survival (OS) was not reached at the 
median follow-up of 81 months. The immunoreactivity 
status was not a statistically significant TTFT or OS 
predictor.
Circulating Ab are produced by the polyclonal 
B-cell population and not by the leukemic clone
To determine whether the circulating Ab detected 
by SERPA in patients’ sera were partly produced by a 
class-switched sub-clone derived from the leukemic 
clone, we first analyzed the IGHV repertoire of patients 
who shared the same Ag recognitions. Patients with 
similar immunoreactivities did not exhibit the same 
IGHV rearrangements. In addition, the analysis of the 
complementarity determining region 3 (CDR3) revealed 
that 6 out of 35 CLL patients displayed stereotyped 
B-cell receptor (BCR) and belonged to 4 subsets, with 
no association between stereotypy and Ag recognition. 
As a confirmatory evidence, we cloned and produced a 
soluble derivative of the leukemic BCR (ScFv-Fc) from 
patient 10 and blotted it in parallel with the whole patient’s 
serum on two identical autologous proteomic maps. The 
patient’s serum recognized 5 Ag, but none of these was 
also recognized by the autologous tumor-derived ScFv-
Fc (Supplementary Figure S1). Taken together, these 
results indicate that the Ab detected by SERPA are entirely 
produced by the normal B-cell population, and do not 
include a soluble fraction of the leukemic BCR.
Alpha-enolase (ENO1) is the most frequently 
recognized Ag and is overexpressed by 
proliferating CLL cells of the LN
ENO1 was the most relevant Ag recognized by 
patients’ sera, since ENO1-specific circulating Ab were 
detectable in 19 out of 35 (54%) CLL sera and in none 
of the HD sera (p=0.006) (Table 1). To confirm the MS 
identification of the protein, we incubated the proteomic 
maps obtained from the tumor cells of 10 anti-ENO1 
Ab+ (patients 22, 23, 24, 25, 26, 27, 29, 31, 32, 33) and 
4 anti-ENO1 Ab- patients (patients 28, 30, 34, 35) with 
a commercially available anti-ENO1 polyclonal Ab. The 
anti-ENO1 Ab generated the same Ag spots produced by 
the sera of patients with CLL (Supplementary Figure S2).
ENO1 expression pattern was investigated 
by immunohistochemistry and multicolor 
immunofluorescence confocal microscopy in lymph node 
(LN) sections obtained from 3 CLL and 3 reactive (R) LN. 
The CLL LN displayed an almost complete effacement 
of the normal architecture by CLL cells and evidence of 
morphologically distinct pseudo-follicles, comprising 
areas rich in prolymphocytes and paraimmunoblasts. 
The anti-ENO1 Ab stained all CLL and R LN, and 
higher magnification indicated an increased expression 
in correspondence of proliferating cells of both CLL and 
R LN sections, at least on the basis of cell morphology 
(Figure 3A and 3B). Multicolor tissue immunofluorescence 
was then used to determine which cells were mostly 
ENO1+. The anti-ENO1 Ab was combined with anti-CD2 
and anti-CD23 Ab to detect T and B cells, respectively. 
In the CLL LN ENO1 reactivity was mostly associated 
to the CD23+ population, while in the R LN it was 
mostly associated to the CD2+ T cells (Figure 3C–3E). 
Ki67 was then used to identify proliferating cells in both 
tissues. Within the CLL LN a significant proportion of 
proliferating B cells was apparent and these cells were 
intensely ENO1+. Conversely, in the reactive LN the 
most of the proliferating cells were CD2+, and they also 
showed ENO1 reactivity, suggesting that ENO1 is highly 
expressed by proliferating cells, independently of the 
lineage (Figure 3D–3K).
ENO1 is transferred on the surface of CLL cells 
undergoing apoptosis
ENO1 expression was also evaluated in the PB 
compartment. First, we compared the intracellular 
expression of ENO1 in PB mononuclear cells (PBMC) 
subpopulations from CLL patients. Cytofluorimetric 
analysis showed that CD19+/CD5+ CLL cells, CD14+ 
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Table 2: Immunoreactivity of patients with CLL
Patient
No of 
recognized 
proteins
Anti-
ENO1 
Ab
Binet Disease state IGHV V-D-J
Stereotyped 
receptor 
subset
Cytogenetics 
by FISH
Hypogamma-
globulinemia
01 2 + A stable UM 1-18/6-19/4 #1 del(17p) yes
02 1 - A stable UM 1-18/3-3/6 del(13q)
03 0 - UM 3-23/4-23/4
04 1 - A stable UM 1-2/1-26/6 #28 del(11q) yes
05 5 + B progression M 4-34/3-3/4 #4 normal yes
06 6 - stable M 5-51/2-2/5 del(13q)
07 1 - A stable n.d. normal yes
08 8 - A stable M 3-33/3-22/4 del(17p) yes
09 1 + A stable M 4-34/5-5/6 #4 tris(12) no
10 6 + B progression M 3-64/6-6/4 del(13q) yes
11 5 + C progression UM 3-23/5-5/4 del(13q)
12 4 - A stable M 4-39/6-6/4 tris(12) no
13 2 + A stable M 5-51/2-2/6 del(11q) yes
14 0 - M 4-34/n.d./6 normal no
15 3 + B stable M 2-5/6-13/5 tris(12) yes
16 3 + A progression UM 4-59/3-22/6 normal yes
17 0 - A stable UM 3-33/3-3/6 normal no
18 1 - A progression UM normal no
19 0 - A stable UM 5-a/6-19/4 #1 normal no
20 0 - B stable n.d. del(17p) yes
21 1 + A progression M 2-70/5-24/4 tris(12) yes
22 20 + B progression UM 3-30/2-2/5 del(17p) no
23 5 + B progression UM 3-11/3-22/4 del(11q) yes
24 2 + B stable M 3-66/3-16/4 del(11q) yes
25 12 + B progression M 3-23/3-22/3 normal no
26 10 + A stable M 3-7/2-2/4 normal yes
27 1 + A stable UM 4-59/3-22/6 normal
28 0 - B stable UM 3-33/4-17/4 del(13q) no
29 19 + B progression M 3-74/3-10/4 normal no
30 1 - A stable M 3-53/6-13/4 del(13q) no
31 1 + UM 4-39/5-12/5 normal
32 5 + A stable UM 1-69/3-3/6 #7 normal no
33 9 + A stable M 7-4/7-27/4 del(13q) yes
34 6 - A stable UM 3-53/n.d./4 del(13q) yes
35 3 - A stable UM 3-9/6-19/6 tris(12) no
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monocytes, and CD3+ T lymphocytes expressed ENO1 at 
the intracellular level (Figure 4A).
We then evaluated the membrane expression of 
ENO1. ENO1 was not expressed on the surface of CD19+/
CD5+ leukemic cells, whereas it was expressed to higher 
extent by CD14+ monocytes, and in a proportion of 
CD3+ T lymphocytes (Figure 4B). After 4 days of in vitro 
culture, the mean fold increase in the percentage of cells 
expressing ENO1 on the surface was significantly higher 
in the apoptotic (Annexin-V+ [AnnV+]) than in the viable 
(AnnV-) fraction of CD19+ cells (p=0.02) (Figure 4C). 
This difference in ENO1 surface expression (mean fold 
increase) was not observed between the apoptotic and 
viable fraction of CD19- cells (Figure 4D).
Immunoreactivity toward ENO1 associates with 
CLL progression and shorter TTFT
The presence of circulating anti-ENO1 Ab was 
not associated with the occurrence of clinically evident 
autoimmune manifestations. By contrast, ENO1 reactivity 
was significantly associated to parameters of disease 
progression such as higher lymphocyte counts (p=0.02) 
and lower platelet numbers (p=0.007) (Supplementary 
Figure S3A and S3B). Similarly, anti-ENO1 Ab (Figure 
5A) were more frequently detected in sera from patients 
with progressive disease than in sera from patients with 
stable disease (p<0.0001). As expected, log-rank test 
indicated that the presence of anti-ENO1 Ab in patients’ 
sera was a negative TTFT predictor in univariate analysis: 
the median TTFT of anti-ENO1 Ab+ CLL patients was 7 
months, whereas that of anti-ENO1 Ab- CLL patients was 
107 months (p=0.01) (Figure 5B). Lastly, we observed 
that the total level of serum IgG was significantly lower 
in anti-ENO1 Ab+ compared to anti-ENO1 Ab- CLL sera 
(p=0.02) (Supplementary Figure S4).
Serum Ab are not able to trigger complement 
dependent cytotoxicity (CDC) and antibody 
dependent cellular cytotoxicity (ADCC)
Next, we asked whether the circulating Ab identified 
in patients sera were effective in triggering CDC. We 
first tested the efficacy of our samples of CLL sera as 
source of complement. As expected, the viability of CLL 
cells exposed to the monoclonal Ab alemtuzumab was 
significantly reduced compared to untreated controls 
(p<0.01). By contrast, we did not observe any significant 
decrease in cell viability when CLL cells were exposed to 
patients’ sera, in the absence of alemtuzumab (Figure 6A–
6D). Flow cytometry revealed that there was no deposition 
of the complement component 4 on the surface of CLL 
cells after incubation with patients’ sera (data not shown). 
Overall, these data show that the circulating Ab detected 
by SERPA in CLL sera are not able to induce CDC toward 
CLL cells.
We then performed CDC assays with sera from 
anti-ENO1 Ab+ patients and the U937 cell line, which 
expresses high levels of surface ENO1 (Figure 6E). Again, 
no modification of cell viability was observed when U937 
cells were treated with anti-ENO1 Ab+ sera, even when 
sera were used at 100% concentration (Figure 6F and 6G). 
These data demonstrate that the circulating Ab do not 
trigger CDC at the in vivo concentrations, even when the 
Figure 2: The number of recognized Ag was significantly higher in patients with progressive CLL than in patients 
with stable disease. The number of recognized Ag was correlated with parameters of disease progression collected at the time of 
SERPA. Disease progression was evaluated according to IWCLL/NCI-WG 2008 guidelines for CLL. Patients with progressive CLL (n=10) 
recognized a significantly higher number of spots compared to patients with stable CLL (n=22) (p=0.01). Box and whiskers plots represent 
median values, first and third quartiles, and minimum and maximum values for each dataset.
Oncotarget7www.impactjournals.com/oncotarget
Figure 3: In lymph node ENO1 is significantly more expressed by proliferating CLL cells. ENO1 expression was evaluated 
by immunohistochemistry and immunofluorescence confocal microscopy on CLL and R LN sections. Anti-ENO1 immunostaining of a 
representative CLL LN and R LN section was performed using an anti-mouse HRP-conjugated secondary Ab and 3,3′-diaminobenzidine 
(brown signal). Black arrows indicate paraimmunoblasts (A) and centroblasts (B). Original magnification x4 (left panels) and x40 (right 
panels). Images were obtained using a Olympus BX41 microscope, equipped with Nikon Coolpix camera. Triple staining of representative 
CLL and R LN sections with anti-ENO1 (red), anti-CD23 (green) and anti-CD2 (white). Original magnification x63; zoom factor of 
2.5 for images on the right. Scale bars represent 50 μm and 25 μm, respectively (C, D). Cumulative data of ENO1 mean pixel intensity 
(arbitrary units) confirmed a significantly higher intensity of ENO1 expression in close proximity of B cells in CLL LN and T cells in R 
LN (always p<0.0001) (E). Triple staining of representative CLL and R LN sections with anti-ENO1 (red), anti-CD23 (green) and anti-
Ki67 (blue). Original magnification x63; zoom factor of 2.5 for images on the right. Scale bars represent 50 μm and 25 μm, respectively 
(F, G). Quantitative measurements of ENO1 mean pixel intensity (arbitrary units) confirmed that CD23+/Ki67+ proliferating cells of the 
CLL LN expressed significantly higher level of ENO1 compared to the CD23+/Ki67- resting fraction (p<0.0001) and to CD23+/Ki67+ 
proliferating B cells of the R LN (p<0.0001) (H). Triple staining of representative CLL LN and R LN sections with anti-ENO1 (red), anti-
CD3 (green) and anti-Ki67 (blue). Original magnification x63; zoom factor of 2.5 for images on the right. Scale bars represent 50 μm and 
25 μm, respectively (I, J). Cumulative analysis of ENO1 mean pixel intensity (arbitrary units) confirmed that the CD3+/Ki67+ proliferating 
fraction of the T-cell compartment expressed significantly higher levels of ENO1 than CD3+/Ki67- resting fraction, in both CLL and R 
LN (p<0.001 and 0.03 respectively) (K). For cumulative data, at least 3 randomly chosen fields from 3 different samples were analyzed. 
Samples were analyzed using a TCS SP5 laser scanning confocal microscope (Leica Microsystems) with an oil immersion 63x/1.5 objective 
lens, images were acquired with LAS AF Version Lite 2.4 software and processed with Photoshop (Adobe Systems). ENO1 mean pixel 
intensity was calculated with ImageJ software (http://rsbweb.nih.gov/ij/). Box and whiskers plots represent median values, first and third 
quartiles, and minimum and maximum values for each dataset. Statistical analysis was performed using Mann-Whitney U test.
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Figure 4: ENO1 is translocated on the surface of apoptotic CD19+ cells. ENO1 expression was evaluated in PBMC isolated 
from patients with CLL, at baseline conditions and after 4-day in vitro culture by flow cytometry. A. ENO1 cytoplasmic expression. High 
percentages of ENO1 were expressed in the cytoplasm of CD19+/CD5+ CLL cells, CD14+ monocytes and CD3+ T cells. B. ENO1 surface 
expression. ENO1 was not expressed on the surface of CD19+/CD5+ CLL cells, whereas it was widely expressed by CD14+ monocytes 
and in a proportion of CD3+ lymphocytes. C, D. Surface ENO1 fold increase expression in CD19+ and CD19- cell fractions. Fold increase 
was calculated for each patient as a ratio between the percentage of CD19+/ENO1+ detected after 4-day in vitro culture and the percentage 
of CD19+/ENO1+ cells at baseline. After 4 days of culture, the fold increase in ENO1 expression was significantly higher in the apoptotic 
(AnnV+) than in the viable (AnnV-) fraction of CD19+ cells (p=0.02) (C). By contrast, there was no difference in the fold increase of ENO1 
expression between the apoptotic (AnnV+) and the viable (AnnV-) fraction of CD19- cells (D). Box and whiskers plots represent median 
values, first and third quartiles, and minimum and maximum values for each dataset.
Figure 5: Anti-ENO1 Ab reactivity is associated with parameters of progressive disease and with a shorter TTFT in 
patients with CLL. The presence of circulating anti-ENO1 Ab in sera of patients with CLL was correlated with parameters of disease 
progression and TTFT. Anti-ENO1 Ab were more frequently detected in sera from patients with progressive CLL than in sera from patients 
with stable CLL (p<0.0001) (A). Kaplan-Meier survival curves for TTFT in our cohort of patients stratified on the basis of anti-ENO1 
reactivity are shown. The presence of anti-ENO1 Ab correlated with shorter TTFT (ENO1 Ab+, n=19; ENO1 Ab-, n=16) (p=0.01) (B).
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cognate Ag is highly expressed on the surface of the target 
cells.
In the last set of experiments, we tested the ability 
of anti-ENO1 Ab+ sera to trigger ADCC toward both 
the U937 cell line and primary CLL cells. We found that 
the % of ADCC of U937 cells cultured for 18 hours in 
the presence of 10% diluted anti-ENO1 Ab+ serum and 
HD PBMC, used as effector cells, was not significantly 
increased compared to target cells cultured with PBMC 
alone, in the absence of serum. Similar results were 
obtained using CLL cells as targets (Figure 7A–7D). 
Therefore, we can conclude that the circulating Ab 
detected by SERPA are unable to trigger ADCC against 
leukemic cells.
DISCUSSION
In CLL, cellular immune responses are unable to 
respond to the tumor and they can even support disease 
evolution [22]. The impact of humoral responses toward 
tumor-derived Ag in CLL is largely unexplored. Through 
the use of SERPA we show that 83% of CLL sera have 
circulating Ab toward at least one CLL-derived Ag. 
Interestingly, we observe that sera from progressive CLL 
are significantly more immunoreactive than sera from 
stable CLL.
The circulating Ab detected by SERPA are 
expression of an immune response generated by the 
residual polyclonal B-cell population toward self-Ag. 
We do not observe shared Ag recognition between a 
representative CLL serum and the ScFv-Fc derived from 
the autologous leukemic BCR. On the other hand, patients 
who share the same Ag recognitions do not show recurrent 
IGHV rearrangements or BCR stereotypies. Autoimmune 
phenomena are rather frequent complications of CLL and 
mostly result in autoimmune cytopenias [23]. A clear 
association between autoimmune cytopenias and poor 
prognostic variables, such as high β2-microglobulin, 
CD38 and ZAP70 expression, and unmutated IGHV 
status, has already been described [24–26]. Moreover, 
direct antiglobulin test positivity, even in the absence 
of overt AIHA, associates with adverse prognostic 
factors and shorter OS [27]. In our cohort, we observe a 
significantly higher degree of immunoreactivity in patients 
Figure 6: Serum Ab are not able to trigger CDC toward tumor cells. A-D. Viability of CLL cells incubated for 1 hour with 
different concentrations of CLL serum, in the presence or in the absence of alemtuzumab. Cell viability was determined by Ann-V/PI 
staining and cytofluorimetric analysis on CLL cells purified from patients’ samples. A, B. Representative analyses of AnnV/PI expression 
on CLL cells left untreated or incubated with patient’s serum at 25% (A) and 100% (B) concentration, in the presence or in the absence of 
alemtuzumab. Indicated is the percentage of AnnV/PI double negative (AnnV-/PI-) cells. C, D. Percentage of AnnV-/PI- viable CLL cells. 
Line plots show that cell viability was significantly reduced when CLL cells were exposed to alemtuzumab (p<0.01). By contrast, there was 
no significant decrease in cell viability when CLL cells were exposed to sera alone, both at the 25% (C) and 100% (D) concentrations. E-G. 
CDC assay on the U937 cell line. E. ENO1 surface expression. Representative analyses of ENO1 expression on U937 cells. F. Representative 
analyses of AnnV/PI expression on U937 cells left untreated or incubated with ENO1-Ab+ patients’ sera at 100% concentration. Indicated 
is the percentage of AnnV-/PI- cells. G. Percentage of viable AnnV-/PI- U937 cells. Line plot shows no significant decrease in cell viability 
after exposure of U937 cells to 6 ENO1-Ab+ sera from CLL patients.
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with progressive CLL than in patients with stable disease, 
even though the immunoreactive status is not related to 
adverse prognostic factors.
MS analyses show that the Ab detected by SERPA 
mostly recognize intracellular Ag, such as glycolytic 
enzymes, cytoskeletal elements and ribonucleoproteins. 
Among others, ENO1, a glycolytic enzyme, is the most 
relevant Ag, detected in 19 out of 35 (54%) CLL sera. 
The overexpression of ENO1 is associated with tumor 
development through a process known as Warburg effect 
[28]. The Warburg effect is a metabolic reprogramming, 
which consists in a positive regulation exerted by the 
hypoxia-inducible factor (HIF) on the expression of 
glycolytic enzymes, such as ENO1, occurring when 
cancer cells are exposed to hypoxic conditions [29, 30]. 
Interestingly, CLL cells express the oxygen-regulated HIF-
1α subunit even under normoxia [31], and the expression 
and the transcriptional activity of HIF-1α are further 
upregulated by exposure of CLL cells to stromal cells 
[32]. In the LN, proliferating CLL cells are confined to 
specialized structures called pseudo-follicles, where they 
interact with T lymphocytes and stromal cells. Our data 
show that ENO1 is more expressed in the leukemic cells 
of the CLL LN than in the normal B cells of the R LN, 
and confirm that it is more expressed by the proliferating 
B cells of the pseudo-follicles than by the resting B-cell 
fraction.
Due to its tumor-related overexpression and ability 
to induce humoral and/or cellular immune responses, 
ENO1 has already been classified as a tumor-associated Ag 
in solid cancers, such as pancreatic ductal adenocarcinoma 
(PDA) [12, 33]. Cappello et al. have reported that a DNA 
vaccine coding for ENO1 can elicit anti-ENO1 IgG 
Ab which are able to induce the killing of murine PDA 
cells by CDC [33]. Unexpectedly, in our cohort of CLL 
patients, the presence of anti-ENO1 Ab is prevalent in sera 
from patients with progressive CLL and is predictive of a 
shorter TTFT. One possible reason of the different clinical 
impact exerted by anti-ENO1 Ab in solid tumors and in 
CLL is that ENO1 is highly expressed at the intracellular 
level, but is not expressed on the cell membrane. It is not 
clear how intracellular self-Ag can become immunogenic 
and trigger humoral responses. One possible explanation 
is that overexpressed self-proteins are exposed during the 
apoptotic turnover of the leukemic cells, thus becoming 
visible and capable of inducing autoreactive immune 
Figure 7: Anti-ENO1 Ab are not able to trigger ADCC against leukemic cells. A-C. % of ADCC of CFSE labelled CLL cells 
co-cultured for 18 hours with HD PBMC, in presence or absence of 10% diluted anti-ENO1 Ab+ serum. Cell lysis was determined by PI 
staining and flow cytometry. % of ADCC was calculated by the formula % PI (T + E + serum) - % PI (T) / % PI (triton X treated T) – % 
PI (T). A, B. Representative analysis of CFSE/PI expression on CLL cells (gated on CFSE+ cells) purified from one patient’s sample 
co-cultured with HD PBMC, used as effector cells, in the absence (A) or presence (B) of anti-ENO1 Ab+ serum at 10% concentration. 
Indicated is the % of CFSE/PI double positive cells. C. Bar graph show no significant differences in the % of ADCC of primary CLL cells 
cultured with PBMC and 10% diluted anti-ENO1 Ab+ serum (n=6) compared to target cells cultured with PBMC alone, in the absence of 
serum. D-F. ADCC assay on U937 cell line. D, E. Representative analysis of CFSE/PI expression on U937 cells (gated on CFSE+ cells) 
co-cultured with HD PBMC, used as effector cells, in the absence (D) or presence (E) of anti-ENO1 Ab+ serum at 10% concentration. 
Indicated is the % of CFSE/PI double positive cells. F. Bar graph show no significant differences in the % of ADCC of U937 cells cultured 
with PBMC and 10% diluted anti-ENO1 Ab+ serum (n=6) compared to target cells cultured with PBMC alone, in the absence of serum. 
Mean results from three different experiments.
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responses. This hypothesis is corroborated by our data 
showing that after 4 days of in vitro culture, the mean fold 
increase in the percentage of cells expressing ENO1 on 
the surface is significantly higher in the apoptotic than in 
the viable fraction of CD19+ cells. The higher frequency 
of immunoreactivities detected by SERPA in the sera of 
patients with progressive CLL can be explained by the 
observation that in advanced-stage CLL the malignant 
clone, which in early-stage is arrested in G0/G1, evolve 
into an autonomously proliferating cell population 
showing a greater ability to enter spontaneous apoptosis 
[34]. In the appropriate context, such as in the spleen 
and LN, where T cells may induce the activation and Ag 
presentation by B cells, this turnover potentially leads to 
a greater exposition of intracellular overexpressed Ag and 
to the production of autoreactive Ab.
To functionally characterize the humoral responses 
detected by SERPA we evaluated the in vitro ability 
of patients’ sera to kill primary CLL cells by CDC or 
ADCC. Deficiencies or reduced levels in one or more 
complement components have already been reported in 
CLL patients [35, 36]. However, we demonstrated that 
CLL sera behave as proper source of complement, in 
inducing alemtuzumab-mediated CDC as effectively as 
HD sera. By contrast, in the absence of alemtuzumab, 
polyreactive CLL sera are not able to induce complement 
deposition on the surface of CLL cells and do not trigger 
CDC toward primary tumor cells. Similarly, CLL sera 
do not trigger ADCC against CLL cells, in the presence 
of PBMC isolated from HD used as effector cells. A 
further demonstration of the functional incompetence of 
circulating Ab detected by SERPA is the observation that 
CLL patients with immunoreacitive sera, even those with 
polyreactive sera, lack clinically manifest autoimmune 
phenomena. A number of reasons may underlie this 
functional incompetence. First of all, the tumor Ag 
recognized by the circulating Ab are mainly intracellular 
proteins and therefore are not optimal targets for an Ab-
mediated immune response. However, we do not observe 
any cytotoxicity even when the U937 cell line, which 
expresses high levels of surface ENO1, is used as target for 
the CDC and ADCC assays. In line with these results is the 
observation that the absolute number of monocytes, which 
also express high levels of surface ENO1, is not decreased 
in the PB of CLL patients with anti-ENO1 circulating Ab 
(data not shown). These findings show that Ab-related 
issues, such as low sera concentrations of the circulating 
Ab and/or low binding affinity toward the corresponding 
Ag, may also contribute to the functional incompetence of 
the humoral responses detected by SERPA.
Overall, our results show that the Ab responses 
detected by SERPA are an epiphenomenon of a disrupted 
immune system, which is unable to control disease 
evolution. It has already been reported that the chronic 
inflammation state determined by an enhanced and 
persistent activation of humoral immune responses, in 
combination with the suppressed cellular anti-tumor 
immunity, may favour the tumor progression and support 
disease evolution [37]. In this context, it will be of interest 
to determine the immunomodulatory properties of the 
new BCR inhibitors, which have now been introduced 
in the clinical practice for the treatment of CLL. Current 
studies already show a recovery of humoral immunity 
and normal B-cell numbers in patients on ibrutinib, 
leading to a decrease in the rate of infections [38]. This 
observation, together with the promising results obtained 
in experimental models of autoimmune diseases [39, 
40], support the hypothesis of an ibrutinib-induced 
immunomodulation which may contribute to tumor 
control.
MATERIALS AND METHODS
Patient population
PB samples were collected from a total of 86 
patients with untreated CLL, after their informed consent, 
in accordance with the Declaration of Helsinki and 
approval by the local institutional review board. Sections 
of LN infiltrated by CLL cells and reactive R LN were 
obtained from the Department of Medical Sciences of the 
University of Torino, Italy. The diagnosis and progression 
of CLL were defined according to International Workshop 
on CLL-National Cancer Institute (IWCLL/NCI-WG) 
guidelines [41]. The disease was defined stable in absence 
of signs of progression. A cohort of 35 patients with CLL 
was analyzed by SERPA. Patients’ biological and clinical 
features were collected, when available, by chart review 
(Supplementary Table S2). The median follow-up of all 
patients was 81 months. The IGVH mutational status 
and the CDR3 clustering analyses were performed as 
previously reported [42, 43]. The control group consisted 
of 12 HD kindly provided by the local blood bank.
Cells and serum samples
PBMC and purified B lymphocytes were prepared 
as described [32]. Serum samples were isolated from PB 
by centrifugation and stored at -80°C until use. In selected 
experiments, the human cell line U937 (ATCC, CRL 
1593.2) was used.
Sample preparation and 2-Dimension 
Electrophoresis (2-DE)
Pellets obtained from at least 107 purified CLL 
cells were solubilized in lysis buffer (urea 9M, CHAPS 
4%, Na3VO4 1mM, DTT 80mM, protease inhibitors and 
nuclease). Samples were spun down at 13800 g for 10 
minutes at 4°C. The clear supernatant was quantified 
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with DC Protein assay kit (Bio-Rad, Hercules, CA, 
USA). 2-DE on ready-made IPG strip (7-cm IPG 
strips, pH 3-10NL; Bio-Rad) was performed essentially 
as described [44]. The 2-DE maps were obtained in 
duplicate and stained with Coomassie Blue or transferred 
onto a nitrocellulose membrane (GE Healthcare 
Biosciences GmbH, Uppsala, Sweden) for serological 
analysis. The 2-D gel images were acquired using the 
ChemiDoc MP system (Bio-Rad).
Western blot analysis
The membrane was incubated overnight at 4°C with 
serum, as primary Ab at working dilution of 1:100, with 
a single chain variable fragment-fragment crystallisable 
region (ScFv-Fc) or with an anti-ENO1 Ab (Santa Cruz 
Biotechnology, Inc; CA, USA). Then the membrane was 
incubated with an anti-human (Santa Cruz Biotechnology, 
Inc) or anti-mouse (GE Healthcare Biosciences GmbH) 
IgG HRP-conjugated Abs. Images were acquired by the 
ChemiDoc MP system (Bio-Rad).
Protein identification by MS
MS analysis was performed as described [44]. The 
25 most intense masses were used for database searches 
against the Swiss-Prot database using the free search 
program Mascot (http://www.matrixscience.com). Only 
proteins with a Mascot score greater than 56 were taken 
into consideration.
ScFv-Fc production
VH and VL genes were amplified with specific 
primers from CLL derived cDNA as already described 
[45]. V genes were assembled as ScFv and cloned in 
fusion with the human Fc region (as scFv-Fc) in the 
pUCOE vector [46]. CHO-S cell line was transfected and 
stable clones was obtained for ScFv-Fc expression. Ab 
produced in cell culture supernatants were purified using 
a protein A/G column.
Flow cytometry
ENO1 surface and intracytoplasmic expression 
was evaluated cytofluorimetrically on B cells, T cells and 
monocytes in PB samples as reported in Supplemental 
Methods.
Cell culture and viability assay
PBMC from patients with CLL were cultured as 
described [32]. The percentage of viable and apoptotic 
cells was determined by Annexin-V (AnnV) or AnnV/
Propidium Iodide (PI) staining with the MEBCYTO-
Apoptosis Kit (MBL Medical and Biological Laboratories, 
Naka-ku Nagoya, Japan).
Immunohistochemistry and confocal 
immunofluorescent microscopy
Cell morphology and numbers were studied by 
Giemsa staining. For immunocytochemistry, coverslips 
were stained as detailed in Supplemental Methods. 
Formalin-fixed, paraffin-embedded sections of CLL or 
R LN were stained and analyzed by light microscopy as 
already described [47] (details in Supplemental Methods).
CDC and ADCC assays
For CDC, purified CLL cells (2 x 105) were incubated 
in presence or absence of alemtuzumab (10 μg/ml) for 30 
minutes at room temperature. CLL cells were then washed 
with PBS and incubated with selected patients’ sera at 
different dilutions for 60 minutes at 37°C. U937 cells were 
incubated only with CLL patients’ sera. Cell viability was 
evaluated using AnnV/PI staining (details in Supplemental 
Methods). For ADCC, purified CLL cells or U937 cells, 
used as target cells (T), were labeled with CFSE (5 μM) for 
30 minutes at 37 °C. CLL cells and U937 cells were then 
incubated with PBMC from healthy donors, used as effector 
cells (E) for 18 hours at 30:1 E:T ratio, in the presence or 
absence of 10% diluted CLL patients’ sera. At the end of the 
co-culture target cells viability was evaluated by PI staining. 
% of ADCC was calculated as follow: % PI (T + E + serum) 
- % PI (T) / % PI (triton X treated T) – % PI (T).
Statistical analysis
Statistical analyses were performed with GraphPad 
Prism (San Diego, CA, USA). Continuous variables 
were compared by Mann-Whitney U (unpaired data) or 
Wilcoxon signed rank (paired data) tests. The χ2 test was 
used in case of dichotomous variables. OS and TTFT 
were defined as the time between the date of SERPA and, 
respectively, the date of death or last follow-up and the 
date of first-line treatment or the last follow-up. OS and 
TTFT were estimated by the Kaplan-Meier method and 
the difference between groups was assessed by log-rank 
test. A p value <.05 was considered significant.
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